albumin-bound paclitaxel / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 274 Diseases   1060 Trials   1060 Trials   12189 News 


«12345678910111213...178179»
  • ||||||||||  5-fluorouracil / Generic mfg.
    Reimbursement, US reimbursement, Journal:  The Trends and Outcomes of Initial Palliative Chemotherapy in Patients with Pancreatic Cancer in Korea Based on National Health Insurance Service Data. (Pubmed Central) -  Jun 19, 2024   
    Background/Objectives: The survival rate of patients with pancreatic cancer (PC) has improved gradually since the introduction of FOLFIRINOX (FFX) and gemcitabine + albumin-bound paclitaxel (GnP) regimens...As initial palliative chemotherapy, 3823 patients (25.90%) received gemcitabine alone; 2779 (18.83%) received gemcitabine + erlotinib; 1948 (13.20%) received FFX; and 1767 (11.97%) received GnP...Radiation therapy (aHR, 0.667; 95% CI, 0.612-0.728) and second-line chemotherapy (aHR, 0.639; 95% CI, 0.597-0.684) were significantly associated with improved survival. Our study found that first-line chemotherapy with FFX was associated with significantly longer survival than the other regimens, although caution is needed in interpreting the results.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca, Ilaris (canakinumab) / Novartis
    Trial completion date, Trial primary completion date, Metastases:  CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov) -  Jun 17, 2024   
    P2,  N=41, Active, not recruiting, 
    Treatment duration and time to death tended to increase over time and did not differ numerically between FOLFIRINOX and GEM + nab-PTX. Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, lobaplatin (D19466) / AEterna Zentaris
    Journal:  A case report of cStage IIIB squamous cell lung carcinoma completely resected after downstaging with neoadjuvant therapy. (Pubmed Central) -  Jun 17, 2024   
    This comprehensive treatment approach underscores the importance of neoadjuvant therapy in optimizing surgical outcomes and improving long-term prognosis for patients with locally advanced lung cancer. For patients with stage III locally advanced lung squamous carcinoma, the combination of Sintilimab and Platinum-based drugs can be used as a neoadjuvant therapy which can reduce the difficulty of the operation.
  • ||||||||||  albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
    Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients. (Pubmed Central) -  Jun 17, 2024   
    All the unresected metastatic pancreatic ductal adenocarcinoma (PDAC) consecutive patients who received GEM-NAB (institution 1) or GEM alone (institutions 2 and 3) as second-line treatment after failure of a 5-fluorouracil based systemic chemotherapy regimen were screened. The issues of the article is based on the trade-off between the benefit in terms of OS of patients treated with GEM-NAB, which is minor (a gain of 2?months of survival, with an accumulated rate of grade???3 non-hematological adverse effects) and the additional institutional cost (
  • ||||||||||  paricalcitol / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
    Trial completion date, Metastases:  Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (clinicaltrials.gov) -  Jun 16, 2024   
    P2,  N=24, Active, not recruiting, 
    Also, MCF7-CHI-R cells were resistant to GEM, ADM, DXT, nab-PTX and PTX. Trial completion date: Jul 2024 --> Dec 2024
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Trial completion date, Trial primary completion date, Combination therapy, Tumor mutational burden, IO biomarker, Metastases:  Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study) (clinicaltrials.gov) -  Jun 13, 2024   
    P2,  N=115, Recruiting, 
    Trial primary completion date: Jun 2024 --> Nov 2024 Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
  • ||||||||||  docetaxel / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Trial suspension:  Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients (clinicaltrials.gov) -  Jun 12, 2024   
    P1/2,  N=74, Suspended, 
    Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026 Recruiting --> Suspended
  • ||||||||||  relacorilant (CORT125134) / Corcept Therap
    Review, Journal:  Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives. (Pubmed Central) -  Jun 11, 2024   
    Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.
  • ||||||||||  Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
    Journal:  Self-Assembled Micelles Based on Ginsenoside Rg5 for the Targeted Treatment of PTX-Resistant Tumors. (Pubmed Central) -  Jun 11, 2024   
    With the aid of the inherent amphiphilic molecular structure and pharmacological effects of ginsenoside Rg5, the prepared RPM enhances the water solubility and active targeting of PTX, inhibiting chemotherapy resistance in cancer cells. Moreover, the polymeric micelles demonstrated favorable anti-inflammatory and neuroprotective effects, providing ideas for the development of new clinical anti-PC preparations.
  • ||||||||||  Vesanoid (tretinoin) / Roche
    Enrollment closed, Phase classification, Trial completion date, Trial primary completion date, Stroma:  STARPAC2: A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer (clinicaltrials.gov) -  Jun 5, 2024   
    P2,  N=170, Active, not recruiting, 
    Recruiting --> Suspended Not yet recruiting --> Active, not recruiting | Phase classification: P2b --> P2 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Feb 2024 --> Nov 2024
  • ||||||||||  Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
    Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) -  Jun 3, 2024   
    P3,  N=271, Active, not recruiting, 
    It is important to evaluate the presence of BRCA mutations in patients with PACC prior to treatment. Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
  • ||||||||||  nintedanib / Generic mfg.
    Phase classification, Trial termination, Monotherapy, Metastases:  STU 022016-083: Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer (clinicaltrials.gov) -  Jun 2, 2024   
    P1/2,  N=14, Terminated, 
    In the treatment of RMHSCC/RMLSCC with TP + PD-1 inhibitors, survival rates of patients can be improved while ensuring the safety of the treatment regimen. Phase classification: P1b --> P1/2 | Active, not recruiting --> Terminated; The study was terminated due to futility and lack of future funding
  • ||||||||||  carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
    Efficacy and safety of concurrent chemoradiotherapy with carboplatin and nanoparticle albumin-bound paclitaxel. (PS-27; Poster board no. 1) -  May 31, 2024 - Abstract #ERS2024ERS_5056;    
    Background: Standard treatment for unresectable locally advanced non-small cell lung cancer (NSCLC) is concurrent platinum-based chemotherapy and thoracic radiation therapy, with the addition of durvalumab maintenance therapy for one year. CCRT with CBDCA and napPTX for unresectable locally advanced NSCLC showed the comparable efficacy and safety with the previous reports.
  • ||||||||||  cobolimab (TSR-022) / GSK, Jemperli (dostarlimab-gxly) / GSK, Zejula (niraparib) / GSK, J&J
    Trial completion date, Combination therapy, Metastases:  Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (clinicaltrials.gov) -  May 29, 2024   
    P1,  N=58, Active, not recruiting, 
    CCRT with CBDCA and napPTX for unresectable locally advanced NSCLC showed the comparable efficacy and safety with the previous reports. Trial completion date: Apr 2024 --> Aug 2024
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment closed, Trial completion date, Combination therapy, Checkpoint inhibition, Metastases:  LAPTOP: Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. (clinicaltrials.gov) -  May 28, 2024   
    P1/2,  N=40, Active, not recruiting, 
    Trial completion date: May 2027 --> May 2029 Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024